Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,039

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nanoparticles in cancer therapy and diagnosis

Brigger, Irène, Dubernet, Catherine, Couvreur, Patrick·2002·Advanced Drug Delivery Reviews
DOI 10.1016/s0169-409x(02)00044-3
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0169-409x(02)00044-3

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 92

  1. Jain, 1987, Transport of molecules in the tumor interstitium: a review, Cancer Res., 47, 3039
  2. Jain, 2001, Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function, J. Control. Release, 74, 7, 10.1016/S0168-3659(01)00306-6 · DOI · Paper page
  3. Seymour, 1992, Passive tumor targeting of soluble macromolecules and drug conjugates, Crit. Rev. Ther. Drug Carrier Syst., 9, 135
  4. Baban, 1998, Control of tumor vascular permeability, Adv. Drug Deliv. Rev., 34, 109, 10.1016/S0169-409X(98)00003-9 · DOI · Paper page
  5. Hobbs, 1998, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA, 95, 4607, 10.1073/pnas.95.8.4607 · DOI · Paper page
  6. Yuan, 1995, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55, 3752
  7. Unezaki, 1996, Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy, Int. J. Pharm., 144, 11, 10.1016/S0378-5173(96)04674-1 · DOI · Paper page
  8. Links, 1999, Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs, Expert Rev. Mol. Med., 1, 1, 10.1017/S1462399499001099X · DOI
  9. Krishna, 2000, Multidrug resistance (MDR) in cancer—mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur. J. Cancer Sci., 11, 265
  10. Yuan, 1998, Transvascular drug delivery in solid tumors, Semin. Radiat. Oncol., 8, 164, 10.1016/S1053-4296(98)80042-8 · DOI
  11. Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283
  12. Noguchi, 1998, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues, Jpn. J. Cancer Res., 89, 307, 10.1111/j.1349-7006.1998.tb00563.x · DOI · Paper page
  13. Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5 · DOI · Paper page
  14. Grislain, 1983, Pharmacokinetics and distribution of a biodegradable drug-carrier, Int. J. Pharm., 15, 335, 10.1016/0378-5173(83)90166-7 · DOI · Paper page
  15. Verdun, 1990, Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles, Cancer Chemother. Pharmacol., 26, 13, 10.1007/BF02940287 · DOI
  16. Brasseur, 1980, Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor, Eur. J. Cancer, 10, 1441, 10.1016/0014-2964(80)90053-5 · doi:10.1016/0014-2964(80)90053-5
  17. Couvreur, 1980, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci., 69, 199, 10.1002/jps.2600690222 · DOI
  18. Chiannilkulchai, 1989, Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastasis, Sel. Cancer Ther., 5, 1, 10.1089/sct.1989.5.1 · DOI
  19. Chiannilkulchai, 1990, Hepatic tissue distribution of doxorubicin-loaded particles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice, Cancer Chemother. Pharmacol., 26, 122, 10.1007/BF02897257 · DOI
  20. Soma, 2000, Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro, J. Control. Release, 68, 283, 10.1016/S0168-3659(00)00269-8 · DOI
  21. Daemen, 1995, Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages, Int. J. Cancer, 61, 716, 10.1002/ijc.2910610520 · DOI
  22. Gibaud, 1994, Increased bone marrow toxicity of doxorubicin bound to nanoparticles, Eur. J. Cancer A, 30, 820, 10.1016/0959-8049(94)90299-2 · DOI
  23. Manil, 1995, Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles, Pharm. Res., 12, 85, 10.1023/A:1016290704772 · doi:10.1023/a:1016290704772
  24. Couvreur, 1982, Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles, J. Pharm. Sci., 71, 790, 10.1002/jps.2600710717 · DOI
  25. Blagoeva, 1992, Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles, Mutat. Res., 268, 77, 10.1016/0027-5107(92)90085-G · doi:10.1016/0027-5107(92)90085-g
  26. Rolland, 1989, Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline, Int. J. Pharm., 54, 113, 10.1016/0378-5173(89)90330-X · DOI
  27. Kattan, 1992, Phase I clinical trial and pharmacokinetics evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles, Invest. New Drugs, 10, 191, 10.1007/BF00877245 · DOI
  28. Storm, 1995, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Adv. Drug Deliv. Rev., 17, 31, 10.1016/0169-409X(95)00039-A · DOI · Paper page
  29. Stolnik, 1995, Long circulating microparticulate drug carriers, Adv. Drug Deliv. Rev., 16, 195, 10.1016/0169-409X(95)00025-3 · DOI · Paper page
  30. Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245 · DOI · Paper page
  31. Sharma, 1996, Novel taxol® formulation: polyvinylpyrrolidone nanoparticles-encapsulated taxol® for drug delivery in cancer therapy, Oncol. Res., 8, 281
  32. Mitra, 2001, Tumor targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier, J. Control. Release, 74, 317, 10.1016/S0168-3659(01)00342-X · DOI · Paper page
  33. Torchilin, 1995, Which polymer can make nanoparticulate drug carriers long-circulating?, Adv. Drug Deliv. Rev., 16, 141, 10.1016/0169-409X(95)00022-Y · DOI · Paper page
  34. Jeon, 1991, Protein–surface interactions in the presence of polyethylene oxide. I. Simplified theory, J. Colloid Interface Sci., 142, 149, 10.1016/0021-9797(91)90043-8 · DOI · Paper page
  35. Jeon, 1991, Protein–surface interactions in the presence of polyethylene oxide. II. Effect of protein size, J. Colloid Interface Sci., 142, 159, 10.1016/0021-9797(91)90044-9 · DOI · Paper page
  36. Reszka, 1997, Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice, J. Pharmacol. Exp. Ther., 280, 232
  37. Gulyaev, 1999, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm. Res., 16, 1564, 10.1023/A:1018983904537 · DOI · Paper page
  38. Lode, 2001, Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models, Pharm. Res., 18, 1613, 10.1023/A:1013094801351 · DOI
  39. Bazile, 1995, Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system, J. Pharm. Sci., 84, 493, 10.1002/jps.2600840420 · DOI · Paper page
  40. Peracchia, 1997, Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol), J. Biomed. Mater. Res., 34, 317, 10.1002/(SICI)1097-4636(19970305)34:3<317::AID-JBM6>3.0.CO;2-N · doi:10.1002/(sici)1097-4636(19970305)34:3<317::aid-jbm6>3.0.co;2-n
  41. Peracchia, 1998, Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate–hexadecyl cyanoacrylate amphiphilic copolymer, Pharm. Res., 15, 550, 10.1023/A:1011973625803 · DOI
  42. Allémann, 1996, Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles, Int. J. Cancer, 66, 821, 10.1002/(SICI)1097-0215(19960611)66:6<821::AID-IJC19>3.0.CO;2-5 · DOI
  43. Hawley, 1995, Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics, Adv. Drug. Deliv. Rev., 17, 129, 10.1016/0169-409X(95)00045-9 · DOI · Paper page
  44. Nishioka, 2001, Lymphatic targeting with nanoparticulate system, Adv. Drug Deliv. Rev., 47, 55, 10.1016/S0169-409X(00)00121-6 · DOI
  45. Sakakura, 1992, Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles, Anti-Cancer Drugs, 3, 233, 10.1097/00001813-199206000-00005 · doi:10.1097/00001813-199206000-00005
  46. Hagiwara, 1997, Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer—a pilot study, Anti-Cancer Drugs, 8, 666, 10.1097/00001813-199708000-00004 · doi:10.1097/00001813-199708000-00004
  47. Tokumitsu, 2000, Gadolinium neutron-capture therapy using novel gadopentetic acid–chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor, Cancer Lett., 150, 177, 10.1016/S0304-3835(99)00388-2 · DOI
  48. Juliano, 1999, Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides, Pharm. Res., 16, 494, 10.1023/A:1011958726518 · DOI
  49. Fattal, 1998, Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J. Control. Release, 53, 137, 10.1016/S0168-3659(97)00246-0 · DOI
  50. Aynié, 1999, Sponge-like alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides, Antisense Nucleic Acid Drug Dev., 9, 301, 10.1089/oli.1.1999.9.301 · DOI
  51. Lambert, 2000, Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides, Pharm. Res., 17, 707, 10.1023/A:1007582332491 · DOI · Paper page
  52. Schwab, 1994, Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice, Proc. Natl. Acad. Sci. USA, 91, 10460, 10.1073/pnas.91.22.10460 · doi:10.1073/pnas.91.22.10460
  53. Chavany, 1994, Adsorption of oligonucleotides onto poly(isohexylcyanoacrylate) nanoparticles protects them against nucleases and increases their cellular uptake, Pharm. Res., 11, 1370, 10.1023/A:1018923301967 · doi:10.1023/a:1018923301967
  54. Godard, 1995, Antisense effect of cholesterol–oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles, Eur. J. Biochem., 232, 404, 10.1111/j.1432-1033.1995.tb20825.x · doi:10.1111/j.1432-1033.1995.tb20825.x
  55. Tondelli, 1998, Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres, Nucleic Acids Res., 26, 5425, 10.1093/nar/26.23.5425 · doi:10.1093/nar/26.23.5425
  56. Zimmer, 1999, Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers, Methods: A Companion to Methods in Enzymology, 18, 286, 10.1006/meth.1999.0786 · doi:10.1006/meth.1999.0786
  57. Ganachaud, 1997, Adsorption of single-strand DNA fragments onto cationic aminated latex particles, Langmuir, 13, 701, 10.1021/la960896e · doi:10.1021/la960896e
  58. Lambert, 2000, EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice, Biochem. Biophys. Res. Commun., 279, 401, 10.1006/bbrc.2000.3963 · DOI
  59. Tanaka, 1997, EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells, J. Clin. Invest., 99, 239, 10.1172/JCI119152 · DOI · Paper page
  60. Larsen, 2000, Resistance mechanisms associated with altered intracellular distribution of anticancer agents, Pharmacol. Ther., 88, 217, 10.1016/S0163-7258(99)00073-X · DOI · Paper page
  61. Bennis, 1994, Enhanced cytotoxicity of doxorubicin encapsulated in polyhexylcyanoacrylate nanospheres against multi-drug-resistant tumour cells in culture, Eur. J. Cancer A, 30, 89, 10.1016/S0959-8049(05)80025-5 · DOI
  62. Hu, 1996, On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance, Cancer Chemother. Pharmacol., 37, 556, 10.1007/s002800050428 · doi:10.1007/s002800050428
  63. Colin de Verdière, 1994, Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells, Cancer Chemother. Pharmacol., 33, 504, 10.1007/BF00686509 · DOI
  64. Cuvier, 1992, Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance, Biochem. Pharmacol., 44, 509, 10.1016/0006-2952(92)90443-M · DOI
  65. Colin de Verdière, 1997, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action, Br. J. Cancer, 76, 198, 10.1038/bjc.1997.362 · DOI · Paper page
  66. Pépin, 1997, On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level, J. Chromatogr. B, 702, 181, 10.1016/S0378-4347(97)00362-9 · DOI
  67. Astier, 1988, Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells, Cancer Res., 48, 1835
  68. Nafziger, 1995, Synthesis and antiproliferative effects of a 4′-morpholino-9-methyl anthracycline, J. Antibiot., 48, 1185, 10.7164/antibiotics.48.1185 · doi:10.7164/antibiotics.48.1185
  69. Yokoyama, 1999, Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system, J. Drug Target., 7, 171, 10.3109/10611869909085500 · DOI
  70. Leo, 1997, General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles, Il Farmaco, 52, 385
  71. Kubiak, 1989, Increased cytotoxicity of nanoparticle-carried adriamycin in vitro and potentiation by verapamil and amiodarone, Biomaterials, 10, 553, 10.1016/0142-9612(89)90062-8 · DOI
  72. Soma, 2000, Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles, Biomaterials, 21, 1, 10.1016/S0142-9612(99)00125-8 · DOI · Paper page
  73. Müller, 1990, In vitro model for the degradation of alkylcyanoacrylate nanoparticles, Biomaterials, 11, 590, 10.1016/0142-9612(90)90084-4 · DOI
  74. Stella, 2000, Design of folic acid-conjugated nanoparticles for drug targeting, J. Pharm. Sci., 89, 1452, 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P · DOI · Paper page
  75. Bhalgat, 1998, Green- and red-fluorescent nanospheres for the detection of cell surface receptors by flow cytometry, J. Immunol. Methods, 219, 57, 10.1016/S0022-1759(98)00121-5 · doi:10.1016/s0022-1759(98)00121-5
  76. Väisänen, 2000, Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies, Luminescence, 15, 389, 10.1002/1522-7243(200011/12)15:6<389::AID-BIO626>3.0.CO;2-7 · doi:10.1002/1522-7243(200011/12)15:6<389::aid-bio626>3.0.co;2-7
  77. Santra, 2001, Development of novel dye-doped silica nanoparticles for biomarker application, J. Biomed. Opt., 6, 160, 10.1117/1.1353590 · doi:10.1117/1.1353590
  78. Ghanem, 1993, Labelled polycyanoacrylate nanoparticles for human in vivo, Appl. Radiat. Isot., 44, 1219, 10.1016/0969-8043(93)90068-L · DOI
  79. Wisner, 1996, Indirected computed tomography lymphography using iodinated nanoparticles to detect cancerous lymph nodes in a cutaneous melanoma model, Acad. Radiol., 3, 40, 10.1016/S1076-6332(96)80331-X · doi:10.1016/s1076-6332(96)80331-x
  80. Wisner, 1996, Characterization of normal and cancerous lymph nodes on indirect computed tomography lymphographic studies after interstitial injection of iodinated nanoparticles, Acad. Radiol., 3, S257, 10.1016/S1076-6332(96)80551-4 · doi:10.1016/s1076-6332(96)80551-4
  81. Bonnemain, 1998, Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications—a review, J. Drug Target., 6, 167, 10.3109/10611869808997890 · DOI · Paper page
  82. Moore, 2000, Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model, Radiology, 214, 568, 10.1148/radiology.214.2.r00fe19568 · DOI · Paper page
  83. Zimmer, 1995, MR imaging of phagocytosis in experimental glioma, Radiology, 197, 533, 10.1148/radiology.197.2.7480707 · DOI
  84. Moore, 1997, Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages, J. Magn. Reson. Imaging, 7, 1140, 10.1002/jmri.1880070629 · DOI · Paper page
  85. Enochs, 1999, Improved delineation of human brain tumors on MR images using long-circulating, superparamagnetic iron oxide agent, J. Magn. Reson. Imaging, 9, 228, 10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.0.CO;2-K · DOI · Paper page
  86. Weissleder, 1994, MR lymphography: study of a high-efficiency lymphotrophic agent, Radiology, 191, 225, 10.1148/radiology.191.1.8134576 · DOI
  87. Clément, 1994, Magnetic resonance lymphography—Enhancement patterns using superparamagnetic nanoparticles, Invest. Radiol., 29, S226, 10.1097/00004424-199406001-00075 · doi:10.1097/00004424-199406001-00075
  88. Högemann, 2000, Improvement of MRI probes to allow efficient detection of gene expression, Bioconjug. Chem., 11, 941, 10.1021/bc000079x · DOI · Paper page
  89. Tiefenauer, 1993, Antibody–magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetite resonance imaging, Bioconjug. Chem., 4, 347, 10.1021/bc00023a007 · DOI
  90. Kirsh, 1998, Angiostatin suppresses malignant glioma growth in vivo, Cancer Res., 58, 4654
  91. Li, 2001, Pegylated polycyanoacrylate nanoparticles as tumor necrosis-α carriers, J. Control. Release, 71, 287, 10.1016/S0168-3659(01)00235-8 · DOI
  92. Yoo, 2000, In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugate, J. Control. Release, 68, 419, 10.1016/S0168-3659(00)00280-7 · DOI · Paper page

Cited by

See all 3,039

Metadata

Authors
Brigger, I., Dubernet, C., & Couvreur, P.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2002-09
Volume
54
Issue
5
Pages
631-651
ISSN
0169-409X (ISSN-L)
DOI
10.1016/s0169-409x(02)00044-3
OpenAlex
W2087020662
Cited by
3,039
References
2
FWCI
4.85
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticles in cancer therapy and diagnosis. https://app.cochat.ai/papers/10.1016/s0169-409x(02)00044-3
The paper
Brigger, I., Dubernet, C., & Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews. https://doi.org/10.1016/s0169-409x(02)00044-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.